Log In

 
Glenmark Pharmaceuticals Ltd.
 

08/01/2016 5:35PM

Glenmark Announces the Discovery and Initiation of IND-Enabling Studies of a Novel Bi-Specific Monoclonal Antibody Targeting CD38

  GBR 1342 is the second bi-specific antibody emerging from Glenmark’s BEAT® platform It is also Glenmark’s second clinical candidate targeting an oncology indication GBR 1342 targets CD38, ...